I Will Win This
Seven years ago, at age 26, Jasmin Watson-El’s world turned upside down.
She was lying in a hospital in her hometown of Baltimore, Maryland, unable to feel her arms or her legs, and she had just been diagnosed with multiple sclerosis (MS).
“My brain no longer works the same as it did before,” she says. “It takes longer for words to come to me or to digest information, but I am determined to get back to me and
I have strategies to overcome those obstacles.”
She also joined the MS Mindshift, an educational initiative for people living with MS, sponsored by Bristol Myers Squibb (formerly Celgene). She is an MS Ambassador and speaks to groups about living with the daily uncertainties that MS brings. “I hope I’m showing people that even with
MS, they can get up and live. I look at me, and I look at MS and I think, ‘MS will not win. I will win this.’” More information can be found at www.MSMindShift.com.
Bristol Myers Squibb’s ozanimod is currently in Phase 3 clinical trials for relapsing multiple sclerosis.
The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com